Hong Kong stock surge | BeiGene-B (02627.HK) sees another more than 20% increase, Quadrivalent Influenza Virus Subunit Vaccine selected for commercial insurance innovative drug catalog preliminary review list
According to 36kr Finance APP, Zhonghui Biotech-B (02627.HK) has risen by over 20% again, reaching a high of 54 Hong Kong dollars, setting a new record high. Compared to the IPO price of 12.9 Hong Kong dollars, it has tripled. As of press time, it has increased by 22.65% to 53.6 Hong Kong dollars, with a turnover of 438.522 million Hong Kong dollars, and a total market value exceeding 21 billion Hong Kong dollars.
Latest